Maybe clearing their current ongoing SB royalty commitments, to put them in a more favourable position to negotiate sale of SB/BOT to other potential pharmaceutical companies looking to acquire them.
Other pharmaceutical companies wouldn’t want to buy the business with the obligation of paying ongoing royalties on a growing business.
?
Ann: Trading Halt, page-26
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
0.005(1.35%) |
Mkt cap ! $678.7M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 38.5¢ | 37.5¢ | $1.701M | 4.493M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 523247 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 146093 | 2 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |